Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
Completed · Phase 3 · NCT04379050
Conditions: Parkinson's Disease (PD)
At a glance
- Research payments reported, 2025
- $218,334
- U.S. investigators named
- 10
- Sites paid
- 16
- Planned or actual enrollment
- 130
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-951 (drug)
- Dates
- Started 2020-06-08; completion 2026-04-17
- Results posted
- Not yet
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to continue testing whether ABBV-951 is safe, effective, and tolerable in participants with Parkinson's disease after completion of the parent study M15-741. ABBV-951 is an investigational (unapproved) drug containing levodopa phosphate/carbidopa phosphate (LDP/CDP) given as infusion under the skin for the treatment of Parkinson's Disease. Participants who have successfully completed M15-741 study will immediately enter this…
From ClinicalTrials.gov, last updated 2026-05-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $218,334 in research payments for this study in 2025 (92 payments).
Products named: Vyalev
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sara S. Dhanani, M.D Neurology · Sun City, AZ
- Andrew S. Kern, M.D., M.S. Neurology · Aurora, CO
- Stuart H. Isaacson, MD Neurology · Boca Raton, FL
- Rajesh Pahwa, M.D. Neurology · Kansas City, KS
- Mwiza Ushe, MD Neurology · Saint Louis, MO
- Stephen L. Lee, M.D.,PH.D. Neurology · Lebanon, NH
- Arjun Tarakad Neurology · Houston, TX
- Eleni O. Vaou, M.D. Neurology · San Antonio, TX
- Jason L. Aldred, M.D. Neurology · Spokane, WA
- Jill K. Baird, M.D. Neurology · Vancouver, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Banner Casa Grande Medical Center, AZ $79,281
- Inland Northwest Research LLC $29,899
- Legacy Emanuel Medical Center, OR $24,980
- Regents of University of Colorado $16,597
- Dartmouth Hitchcock Health $16,486
- Parkinson S Disease and Movement $16,046
- Washington Univ Sch of Med $13,382
- University of Kansas Medical Center $12,760
- Baylor College of Medicine $3,361
- University of Texas Health Science $1,943
- Dartmouthhitchcock Clinic $600
- University of Colorado Denver School of Medicine $600
- University of Kansas Medical Center Research Institute Inc $600
- Parkinsons Disease and Movement $600
- Washington University in St Louis $600
- Ut Health San Antonio $600
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.